216 related articles for article (PubMed ID: 935115)
1. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
[TBL] [Abstract][Full Text] [Related]
2. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF
Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
[No Abstract] [Full Text] [Related]
3. Long-term treatment of uraemic osteodystrophy with 1-alpha-hydroxycholecalciferol.
Nielsen SP; Binderup E; Godtfredsen WO; Jensen H; Ladefoged J
Proc Eur Dial Transplant Assoc; 1976; 12():221-6. PubMed ID: 935114
[TBL] [Abstract][Full Text] [Related]
4. 1alpha-Hydroxycholecalciferol in renal osteodystrophy.
Pierides AM; Ellis HA; Ward MK; Simpson W; Kerr DN
Calcif Tissue Res; 1977 May; 22 Suppl():105-11. PubMed ID: 912511
[No Abstract] [Full Text] [Related]
5. 1alpha-hydroxycholecalciferol: a promising therapeutic approach for renal osteodystrophy.
Gotloib L; Mines M; Mazur Y; Sklan D; Garmizo AL; Jancu J; Israeli M; Malul M
Isr J Med Sci; 1978 Jul; 14(7):731-5. PubMed ID: 681163
[TBL] [Abstract][Full Text] [Related]
6. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol.
Bordier PJ; Marie PJ; Arnaud CD
Kidney Int Suppl; 1975 Jan; (2):102-12. PubMed ID: 1057669
[No Abstract] [Full Text] [Related]
7. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF
Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
[No Abstract] [Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
Winney RJ; Bone JM; Anderson TJ; Robson JS
Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
[No Abstract] [Full Text] [Related]
10. [Renal osteodystrophy in two children : a comparison of the effects of 1 alpha-hydroxycholecalciferol (author's transl)].
Chantraine JM; Davin JC; Lambrechts L; Heynen G
Ann Endocrinol (Paris); 1979; 40(2):161-2. PubMed ID: 475307
[TBL] [Abstract][Full Text] [Related]
11. L-alpha-hydroxycholecalciferol treatment of adults with chronic renal failure.
Madsen S; Olgaard K
Acta Med Scand; 1976; 200(1-2):1-5. PubMed ID: 961464
[TBL] [Abstract][Full Text] [Related]
12. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.
Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW
Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961
[TBL] [Abstract][Full Text] [Related]
13. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
Madsen S
Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
[No Abstract] [Full Text] [Related]
14. Vitamin D metabolites and bone mineralization in man.
Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
[TBL] [Abstract][Full Text] [Related]
16. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
[TBL] [Abstract][Full Text] [Related]
17. The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
Junor BJ; Catto GR; Macleod M
Calcif Tissue Res; 1977 May; 22 Suppl():112-6. PubMed ID: 912512
[No Abstract] [Full Text] [Related]
18. [Renal osteodystrophy: the importance of 1-alpha-OH-D3].
Berland Y; Olmer M; Grandvuillemin M; Lachaize AM
Sem Hop; 1981 Mar 8-15; 57(9-10):445-9. PubMed ID: 6261385
[TBL] [Abstract][Full Text] [Related]
19. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
[No Abstract] [Full Text] [Related]
20. 1-alpha-hydroxycholecalciferol for renal osteodystrophy.
Brownjohn AM; Goodwin FJ; Hately W; Marsh FP; O'Riordan JL; Papapoulos SE
Br Med J; 1977 Sep; 2(6089):721-3. PubMed ID: 912269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
